SCHEDULE: L.I.A. Pure Capital Discloses 9.99% Stake in Clearmind Medicine
Beneficial Ownership Report
L.I.A. Pure Capital Ltd. has reported a beneficial ownership of 9.99% in Clearmind Medicine Inc., holding 3,307,291 common shares.
Summary
- L.I.A. Pure Capital Ltd., an entity based in Israel, has disclosed a 9.99% beneficial ownership stake in Clearmind Medicine Inc.
- The reporting person holds 3,307,291 common shares of Clearmind Medicine Inc., with no par value per share.
- L.I.A. Pure Capital Ltd. possesses sole voting power and sole dispositive power over all 3,307,291 shares.
- The 9.99% ownership percentage is calculated based on 33,106,024 common shares issued and outstanding, as reported by Clearmind Medicine Inc. in a prospectus supplement filed with the SEC on November 19, 2025.
- The filing certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer, nor in connection with any transaction having such purpose or effect.
Sentiment
Score: 5
Explanation: This is a neutral, factual disclosure of beneficial ownership. It does not inherently convey positive or negative sentiment about the company's performance, though a significant stake by an institutional investor can be perceived positively by the market.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment in Clearmind Medicine Inc. by L.I.A. Pure Capital Ltd., suggesting potential investor confidence or strategic positioning within the biotechnology or pharmaceutical sector, depending on Clearmind's specific focus. Such a substantial stake by an Israeli capital firm could also hint at international interest in Clearmind's operations or pipeline.
Stakeholder Impact
- Shareholders: Disclosure of a significant institutional investor holding 9.99% of common shares may influence market perception and liquidity, potentially signaling increased institutional interest.
- Company Management: Awareness of a large shareholder may impact strategic decisions and investor relations, as L.I.A. Pure Capital Ltd. now holds a notable stake.
Key Dates
| Date | Description |
|---|---|
| 11/19/2025 | Date of event requiring the filing of this statement, and date of prospectus supplement reporting outstanding shares. |
| 12/01/2025 | Date of signature by Kfir Silberman, CEO of L.I.A. Pure Capital Ltd. |
Keywords
Clearmind Medicine Inc., L.I.A. Pure Capital Ltd., Schedule 13G, Beneficial Ownership, Common Shares, Institutional Investor, Equity Stake, CMND
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.